Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
Rani Therapeutics (NASDAQ: RANI) announced it will present preclinical data for its RaniPill® capsule at ENDO 2025 in San Francisco. The presentation will showcase research demonstrating bioequivalence between oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) using their robotic pill (RT-114) and traditional subcutaneous injection in canines.
The poster presentation, titled "Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114)," will be presented by Dr. Anvesh Dasari on July 14, 2025, from 12:00 PM to 1:30 PM PT, as part of the session on adipose tissue, appetite, and obesity therapeutic advances.
Rani Therapeutics (NASDAQ: RANI) ha annunciato che presenterà dati preclinici sulla sua capsula RaniPill® al ENDO 2025 a San Francisco. La presentazione mostrerà una ricerca che dimostra la bioequivalenza tra la somministrazione orale di un agonista bispecifico dei recettori GLP-1/GLP-2 (PG-102) tramite la loro pillola robotica (RT-114) e l'iniezione sottocutanea tradizionale nei cani.
Il poster, intitolato "Somministrazione orale di un agonista bispecifico dei recettori GLP-1/GLP-2 (PG-102) tramite una pillola robotica (RT-114)", sarà presentato dal dott. Anvesh Dasari il 14 luglio 2025, dalle 12:00 alle 13:30 PT, nell'ambito della sessione dedicata al tessuto adiposo, all'appetito e ai progressi terapeutici nell'obesità.
Rani Therapeutics (NASDAQ: RANI) anunció que presentará datos preclínicos de su cápsula RaniPill® en ENDO 2025 en San Francisco. La presentación mostrará una investigación que demuestra la bioequivalencia entre la administración oral de un agonista bispecífico de los receptores GLP-1/GLP-2 (PG-102) mediante su píldora robótica (RT-114) y la inyección subcutánea tradicional en caninos.
La presentación en póster, titulada "Administración oral de un agonista bispecífico de los receptores GLP-1/GLP-2 (PG-102) a través de una píldora robótica (RT-114)", será presentada por el Dr. Anvesh Dasari el 14 de julio de 2025, de 12:00 p.m. a 1:30 p.m. PT, como parte de la sesión sobre tejido adiposo, apetito y avances terapéuticos en obesidad.
Rani Therapeutics (NASDAQ: RANI)는 샌프란시스코에서 열리는 ENDO 2025에서 RaniPill® 캡슐에 대한 전임상 데이터를 발표할 예정입니다. 이번 발표에서는 로봇 알약(RT-114)을 이용한 이중특이성 GLP-1/GLP-2 수용체 작용제(PG-102)의 경구 투여와 전통적인 피하 주사가 개에서 생물학적 동등성을 보인 연구 결과를 선보일 것입니다.
"로봇 알약(RT-114)을 통한 이중특이성 GLP-1/GLP-2 수용체 작용제(PG-102)의 경구 투여"라는 제목의 포스터 발표는 Dr. Anvesh Dasari가 2025년 7월 14일 오후 12시부터 1시 30분(태평양 시간)까지 지방 조직, 식욕 및 비만 치료 발전 세션의 일환으로 진행할 예정입니다.
Rani Therapeutics (NASDAQ : RANI) a annoncé qu'elle présenterait des données précliniques sur sa capsule RaniPill® lors de ENDO 2025 à San Francisco. La présentation mettra en avant des recherches démontrant la bioéquivalence entre l'administration orale d'un agoniste bispécifique des récepteurs GLP-1/GLP-2 (PG-102) via leur pilule robotisée (RT-114) et l'injection sous-cutanée traditionnelle chez les chiens.
Le poster, intitulé « Administration orale d'un agoniste bispécifique des récepteurs GLP-1/GLP-2 (PG-102) via une pilule robotisée (RT-114) », sera présenté par le Dr Anvesh Dasari le 14 juillet 2025, de 12h00 à 13h30 PT, dans le cadre de la session sur le tissu adipeux, l'appétit et les avancées thérapeutiques contre l'obésité.
Rani Therapeutics (NASDAQ: RANI) gab bekannt, dass es präklinische Daten zu seiner RaniPill®-Kapsel auf der ENDO 2025 in San Francisco präsentieren wird. Die Präsentation zeigt Forschungsergebnisse, die die Bioäquivalenz zwischen der oralen Verabreichung eines bispezifischen GLP-1/GLP-2-Rezeptor-Agonisten (PG-102) mittels ihrer robotischen Pille (RT-114) und der herkömmlichen subkutanen Injektion bei Hunden demonstrieren.
Die Posterpräsentation mit dem Titel „Orale Verabreichung eines bispezifischen GLP-1/GLP-2-Rezeptor-Agonisten (PG-102) mittels einer robotischen Pille (RT-114)“ wird von Dr. Anvesh Dasari am 14. Juli 2025 von 12:00 bis 13:30 Uhr PT im Rahmen der Sitzung zu Fettgewebe, Appetit und therapeutischen Fortschritten bei Fettleibigkeit vorgestellt.
- None.
- None.
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA.
Details of the presentations are as follows:
Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT-114) Achieves Bioequivalence to Subcutaneous Injection in Canines
Session Type: Poster Presentation
Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II
Session Date & Time: July 14, 2025 from 12:00 PM to 1:30 PM PT
Poster Number: MON-691
Presenting Author: Anvesh Dasari, PhD
The abstract presented at ENDO 2025 is available on the Endocrine Society website.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
FAQ
When is Rani Therapeutics (RANI) presenting at ENDO 2025?
What will Rani Therapeutics (RANI) present at ENDO 2025?
Who is presenting the Rani Therapeutics (RANI) research at ENDO 2025?
What is the significance of Rani Therapeutics' (RANI) presentation at ENDO 2025?
